The 375-patient LUMINARA trial found a cardiac-function signal at the lowest AZD5462 dose and lower vascular resistance across all three tested doses, with no excess adverse events reported.
Assaf Pereg becomes Arbe’s CFO on Aug. 30 as the radar company starts production-line deliveries, cuts spending and pursues larger commercial programs.
The customer contracts cover more than 500,000 metric tons of soda ash through December 2028 and are being acquired through Searles Valley Minerals' Chapter 11 proceedings.
The 14,194-patient study found no reduction in cardiovascular death, heart attack or ischemic stroke with milvexian, confirming the trial’s earlier futility stop.
Cytokinetics released new aficamten analyses from ACACIA-HCM and MAPLE-HCM, adding data on cardiac function in non-obstructive HCM and prior beta-blocker use in obstructive HCM.
Tenax presented completed LEVEL analyses at ESC, highlighting a prespecified 26.3-meter subgroup benefit even though the 241-patient Phase 3 trial failed overall.
Bristol Myers reported sustained reductions in cardiac obstruction and symptom improvement through 252 weeks in the single-arm EXPLORER-LTE extension study of Camzyos.
Marriott’s August 29 redemption retires the 5.450% Series LL notes 17 days before maturity, with payment moving to the next business day because the redemption date falls on…
Gabelli’s proposed GRIT ETF reached the effective date designated in its latest SEC amendment after a series of postponements stretching from April through August.
Starting Repatha before PCI lifted 12-month LDL goal attainment to 81.6% from 39.6%, but death or unplanned cardiovascular hospitalization was 14.6% versus 15.4%.